Serum S100B Protein Assay in Mild Head Injury (TCLAS-100B)

• ClinicalTrials.gov Identifier: NCT03345602
• Recruitment Status: Unknown
• First Posted: November 17, 2017
• Last Update Posted: November 17, 2017
• Sponsor: University Hospital, Caen
• Information provided by (Responsible Party): University Hospital, Caen

Study Description

Brief Summary:

Head injuries are a major public health issue, with an estimated annual incidence in Europe of 262 per 100,000 population. Light head injury (SCI), defined by a Glasgow score between 13 and 15, constitutes the majority (71% to 98%) of head injury cases. Despite a generally good prognosis, patients with TCL have a low but real risk of brain damage, whose prevalence is estimated at 5%. Cerebral computed tomography (CT) because of its high sensitivity for the detection of posttraumatic intracranial lesions (LIC), is currently considered the gold standard for the diagnosis of these lesions in patients considered at risk after clinical evaluation. The number of cTCTs performed is high with no lesion in more than 90% of cases. The S100B protein, a marker of brain tissue damage, is reported to reliably exclude the presence of brain lesions in adults as well as antiaggregants. These numerous studies show that its serum assay in combination with the clinical decision algorithms allows, thanks to a sensitivity close to 100% for brain lesions, to reduce the number of CTMc currently prescribed by approximately 30%, and therefore to decrease unnecessary exposure to radiation. Although there is no study on the subject, a gain on the duration of care in emergencies can be expected as well as a reduction on the cost of care by a dosage price three times less higher than the TDMc. Expert opinion for the use of this assay in the management of moderate-risk TCL at threshold ≤ 0.10 μg / L in 3h post-TC to ensure sensitivity of 100%, was published in 2014 in the Annales Françaises de Médecine d'Urgence.

The use of anticoagulants has continued to increase in recent years. In 2013, it is estimated that 3.12 million patients received at least one anticoagulant in France. Currently, the international and French recommendations indicate the achievement of cTCT in anticoagulated TCL because it is an independent risk factor for cerebral injury and is therefore considered to be a high risk TCL. LIC. The hypothesis of this study is that the S100B protein assay could also exclude the presence of brain lesion after TCL under anticoagulation in adults

Condition or disease	Intervention/treatment
Light Head Injury	Diagnostic Test: serum S100B protein assay measurement

Study Design

• Study Type: Observational
• Estimated Enrollment: 400 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Evaluation of the Serum S100B Protein Assay in the Management of Mild Head Injury Under Anticoagulation
• Estimated Study Start Date: March 1, 2018
• Estimated Primary Completion Date: March 1, 2020
• Estimated Study Completion Date: July 1, 2020

Groups and Cohorts

Intervention Details:

• Diagnostic Test: serum S100B protein assay measurement
  serum S100B protein assay measurement within the 3 hours after head trauma

Outcome Measures

Primary Outcome Measures :

1. S100B protein serum concentration [ Time Frame: baseline (maximum 3 hours after head trauma) ]
   The main objective of this study is to evaluate whether a negative serum assay of S100B protein (≤ 0.10 μg / L) within 3 hours after head trauma

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Sampling Method: Non-Probability Sample

Study Population

• Cranial Trauma having induced a Glasgow <13
• Presence of a high risk factor to perform a brain scan (formal indication of cTCT): Focused neurological deficit, Glasgow score <15 at 2 hr, suspicion of open skull fracture or embarrassment, all Sign of fracture of the base of the skull (hemotympanum, bilateral periorbital ecchymosis), otorrhea or rhinorrhea of CSF, convulsion post traumatic.
• Cranial Trauma time unknown
• Fuzzy anamnesis
• Traumatized severe / polytraumatized (victim of a violent trauma, according to the kinetic criteria of Vittel, whatever are the apparent lesions and / or 2 lesions or more of which at least one threatens the vital prognosis)
• Refusal to participate
• Refusal to perform a TDMc
• Congenital or acquired coagulopathy
• Decision not to carry out a TDMc
• Active melanoma

Criteria

Inclusion Criteria:

• Major patient
• Emergency department patient with mild head trauma (13 ≤ Glasgow score ≤ 15)
• Affiliated to the social security scheme
• Patient having been informed about the study and do not disagree to participate
• Patient on anticoagulant therapy (enteral or parenteral route)

Exclusion Criteria:

-

Contacts and Locations

Locations

France

Caen University Hospital

Caen, France, 14000

Contact: Alexandre GUGNE, MD 0231063404 ext +33 guigne-a@chu-caen.fr

Sponsors and Collaborators

University Hospital, Caen

More Information

• Responsible Party: University Hospital, Caen
• ClinicalTrials.gov Identifier: NCT03345602
• Other Study ID Numbers: 17-091
• First Posted: November 17, 2017
• Last Update Posted: November 17, 2017
• Last Verified: November 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Craniocerebral Trauma; Wounds and Injuries; Trauma, Nervous System; Nervous System Diseases